Video walkthrough
Planning Management worked through on the exam interface, with the BNF open, in 10 min.
At a glance
| Question style | Single best answer from five |
|---|---|
| What you do | Single best answer from five |
| Primary skill | Choosing the correct next treatment step |
| BNF use | Treatment summaries, then the relevant monograph |
| On PassthePSA | Single best answer in the exam's layout, explanation cites the BNF pathway. 231 questions in this section, rated easy to hard. |
What this section is really testing
- Identifying the immediate clinical problem and whether it is urgent, because urgency changes which step comes first.
- Knowing first-line rather than merely acceptable treatment, as set out in the BNF treatment summary for the condition.
- Applying patient-specific modifiers: age, ethnicity, renal function, pregnancy, comorbidity and current medicines.
- Sequencing: recognising that a correct treatment can still be the wrong answer if something must happen before it.
A repeatable approach
- Identify the problemDiagnosis or clinical state in one phrase: severe hypercalcaemia, new atrial fibrillation, stage 2 hypertension.
- Decide the urgencyIs the patient unstable? Stabilisation and reversal come before definitive treatment.
- Find the first-line pathwaySearch the condition. The treatment summary lists steps in order.
- Apply the modifiersAge under or over 55, family origin, eGFR, pregnancy, asthma: each moves the answer within the pathway.
- Check it is the next stepNot a later correct step. Not a second-line agent. The one thing that should happen now.
Using the BNF for this section
The exam is open book, and the time is short. Know which heading answers which question before you open the monograph.
| If you need to know | Look under |
|---|---|
| What is first-line for this condition? | Treatment summaries |
| Does this patient change the choice? | The summary's own subheadings, then the monograph's cautions |
| Is the option contraindicated here? | Contra-indications |
| Is it safe with what they take? | Interactions |
The general technique, with timed lookups, is in the BNF guide.
Next step, not any step
Most options in a planning item are real treatments for the condition. The discrimination is sequence. Ask three questions of the option you like.
- BeforeIs there something that must happen first: fluids, oxygen, stopping a drug, correcting a result?
- NowIs this the treatment summary's first-line step for a patient with these modifiers?
- LaterOr is it a second-line or add-on step that only follows if the first fails?
Common traps
| Trap | Why it costs marks |
|---|---|
| Second-line too early | The treatment may be right eventually but is not the initial step. |
| Ignoring the modifier | Renal function, age, pregnancy or family origin changes the standard pathway. |
| Treating the number | An abnormal result does not always need a drug. Sometimes the next step is to stop one. |
| Right treatment, wrong order | Fluids before the bisphosphonate. Oxygen before the antibiotic. Stabilise, then treat. |
| Choosing the familiar drug | The option you have seen most often on the wards is not always the summary's first line. |
Areas worth being comfortable with
Not predictions. These are the broad clinical areas this section draws on, taken from the shape of the exam and the BNF; being fluent in them makes the lookup fast.
- Hypertension: first line by age and family origin, then the add-on sequence
- Type 2 diabetes: escalation after metformin
- Atrial fibrillation: rate versus rhythm, and anticoagulation
- Heart failure with reduced ejection fraction
- Asthma and COPD stepwise treatment
- Acute coronary syndromes and secondary prevention
- Common infections and the antibiotic of first choice
- Hypercalcaemia, hyperkalaemia and other emergencies
- Epilepsy in adults, including women of childbearing potential
- Pain, depression and other symptom-led pathways
What this section covers in the bank
Topics with the most planning management questions at the last build, counted by the app's topic search; each link opens that topic in the app.
- Infection and antibiotics · 30
- Atrial fibrillation and anticoagulants · 28
- Depression, psychosis and mental health · 22
- Angina and heart attack · 20
- Steroids and adrenal · 20
- Stomach, bowel and nausea · 18
- Pain and opioids · 13
- Pregnancy, breastfeeding and contraception · 11
Worked examples
These are real questions from the PassthePSA bank, free to every visitor. Work each one with the BNF open before you show the answer; at exam pace a 2-mark item has 1 min 12 s.
A 72-year-old with watery diarrhoea a week after co-amoxiclav
Case
A 72-year-old woman develops profuse watery diarrhoea 1 week after a course of co-amoxiclav.
PMH: recurrent urinary tract infections.
DH: recent co-amoxiclav (completed), omeprazole 20 mg PO once daily.
On examination: mild abdominal tenderness; afebrile, not shocked.
Investigations: stool toxin testing confirms a first episode of Clostridioides difficile infection; WCC 14 ×10⁹/L (4.0–11.0), creatinine 92 µmol/L (60–110).
Question
Select the most appropriate first-line treatment.
(mark it with a tick)
Management options
- intravenous ceftriaxone
- loperamide
- oral amoxicillin
- oral metronidazole
- oral vancomycin
Show the answer and markingHide the answer
oral vancomycin
Marks2
ExplanationOral vancomycin is first-line for a first episode of C. difficile infection (NICE NG199). Oral fidaxomicin is the second-line choice if vancomycin is ineffective; metronidazole no longer has a first-line role and appears only as intravenous adjunctive treatment, on specialist advice, for refractory or life-threatening infection. Antimotility drugs such as loperamide should be avoided.
© 2026 PassthePSA · Question MAN-20 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).
Antithrombotic treatment four weeks after a stented NSTEMI
Case
A 71-year-old man attends the cardiology clinic 4 weeks after a non-ST-elevation myocardial infarction treated by percutaneous coronary intervention with one drug-eluting stent to the left anterior descending artery. The procedure was uncomplicated, with no arrhythmia or hypotension afterwards, and he has had no further chest pain, no bruising and no bleeding.
PMH: Permanent atrial fibrillation for the past 3 years; hypertension; a Helicobacter pylori-associated duodenal ulcer 12 years ago, eradicated and healed, which never bled; no diabetes; no previous stroke or stent.
DH: apixaban 5 mg PO twice daily (12-hrly) (atrial fibrillation); aspirin 75 mg PO daily (after coronary stent); clopidogrel 75 mg PO daily (after coronary stent); lansoprazole 30 mg PO daily (gastroprotection during combined antithrombotic treatment); bisoprolol 5 mg PO daily; ramipril 5 mg PO daily; atorvastatin 80 mg PO nightly (all three after the infarction). No known drug allergies.
SH: Ex-smoker; drinks 6 units weekly; drives.
On examination: Temperature 36.6°C, HR 72/min and irregularly irregular, BP 128/76 mmHg, RR 14/min, O2 sat 97% breathing air. Weight 88 kg, body mass index 27.9 kg/m². Heart sounds normal, chest clear, no peripheral oedema and no raised jugular venous pressure. No bruising, no purpura and no melaena on rectal examination.
Investigations: Hb 143 g/L (130–175), WCC 6.8 ×10⁹/L (4.0–11.0), platelets 268 ×10⁹/L (150–400) Na⁺ 140 mmol/L (135–145), K⁺ 4.3 mmol/L (3.5–5.3), urea 5.8 mmol/L (2.5–7.0), creatinine 92 µmol/L (60–110), eGFR 77 mL/min/1.73 m² (>60) HbA1c 38 mmol/mol (<42) ALT 26 U/L (<41), bilirubin 11 µmol/L (<21) ECG: atrial fibrillation at 72/min, no ischaemic change
Question
Select the most appropriate antithrombotic regimen to continue from today.
(mark it with a tick)
Management options
- continue apixaban 5 mg oral (PO) twice daily (12-hrly), aspirin 75 mg oral (PO) daily and clopidogrel 75 mg oral (PO) daily until 12 months after the stent
- stop the apixaban and continue aspirin 75 mg oral (PO) daily with clopidogrel 75 mg oral (PO) daily until 12 months after the stent
- stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with clopidogrel 75 mg oral (PO) daily until 12 months after the stent
- stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with ticagrelor 90 mg oral (PO) twice daily (12-hrly) until 12 months after the stent
- stop the aspirin and the clopidogrel and continue apixaban 5 mg oral (PO) twice daily (12-hrly) alone from today
Show the answer and markingHide the answer
stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with clopidogrel 75 mg oral (PO) daily until 12 months after the stent
Marks2
ExplanationCorrect — stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with clopidogrel 75 mg oral (PO) daily until 12 months after the stent. NICE NG185 recommendation 1.4.22 gives the regimen in one sentence: 'For people already on anticoagulation who have had PCI, continue anticoagulation and clopidogrel for up to 12 months.' Aspirin is not in that sentence, and recommendation 1.4.21 explains why it is the one that goes: 'long-term continuation of aspirin, clopidogrel and oral anticoagulation (triple therapy) significantly increases bleeding risk.' The 2023 ESC acute coronary syndromes guideline puts a clock on it — anticoagulant plus a single antiplatelet, 'preferably clopidogrel', is 'the default strategy for up to 12 months after up to 1 week' of triple therapy — and he is 4 weeks out, so the aspirin is already overdue for withdrawal. The dose stays at apixaban 5 mg twice daily: he meets none of the three reduction criteria, being 71 rather than 80 or over, 88 kg rather than 60 kg or less, and having a creatinine of 92 rather than 133 micromol/L or more. The lansoprazole continues alongside, and at 12 months from the stent the clopidogrel stops and the apixaban carries on by itself.
This example on its own page, with the method and checklist →
© 2026 PassthePSA · Question MAN-88 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).
First-line treatment for stage 2 hypertension in a 48-year-old
Case
A 48-year-old man of white British family origin attends to discuss blood pressure readings taken at home.
PMH: nil of note; non-smoker.
DH: no regular medication; no allergies.
On examination: BMI 27 kg/m². Stage 2 hypertension confirmed on ambulatory monitoring (average 152/96 mmHg). No end-organ signs.
Investigations: Na 140 mmol/L (135–145), K 4.3 mmol/L (3.5–5.0), creatinine 84 µmol/L (60–110), eGFR >90 mL/min/1.73m², urine ACR normal, HbA1c 38 mmol/mol.
Question
Select the most appropriate first-line antihypertensive.
(mark it with a tick)
Management options
- amlodipine
- atenolol
- bendroflumethiazide
- doxazosin
- ramipril
Show the answer and markingHide the answer
ramipril
Marks2
ExplanationFor a patient aged under 55 and not of African or Caribbean family origin, NICE recommends an ACE inhibitor (or ARB) first-line. Ramipril is therefore most appropriate; a calcium-channel blocker such as amlodipine would be first-line if he were 55 or over, or of African/Caribbean origin.
This example on its own page, with the method and checklist →
© 2026 PassthePSA · Question MAN-01 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).
Before you submit
- Have I named the problem and its urgency?
- Is this the treatment summary's first-line step, not a later one?
- Have I applied every modifier the case gives me?
- Is anything needed before this step?
- Is the option contraindicated for this patient?
Practise this section
Practise Planning Management on its own, or meet it in exam proportions inside a full mock paper. The practice questions are written to reflect the PSA's format and marking closely; PassthePSA is independent of the assessment provider.
Practise Planning Management questions 231 questions, each with a full explanation
Section sizes and marks follow the published PSA blueprint. The BNF headings named here are the current online BNF's. Check any dose or threshold against the BNF before you rely on it; this page teaches the method, the BNF holds the numbers.